109 related articles for article (PubMed ID: 37579099)
21. Healthcare Patterns of Pregnant Women and Children Affected by OUD in 9 State Medicaid Populations.
Jarlenski M; Kim JY; Ahrens KA; Allen L; Austin A; Barnes AJ; Crane D; Lanier P; Mauk R; Mohamoud S; Pauly N; Talbert J; Zivin K; Donohue JM
J Addict Med; 2021 Sep-Oct 01; 15(5):406-413. PubMed ID: 33560699
[TBL] [Abstract][Full Text] [Related]
22. Community Attitudes Toward Opioid Use Disorder and Medication for Opioid Use Disorder in a Rural Appalachian County.
Beachler T; Zeller TA; Heo M; Lanzillotta-Rangeley J; Litwin AH
J Rural Health; 2021 Jan; 37(1):29-34. PubMed ID: 32738095
[TBL] [Abstract][Full Text] [Related]
23. Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers.
Cochran G; Cole ES; Warwick J; Donohue JM; Gordon AJ; Gellad WF; Bear T; Kelley D; DiDomenico E; Pringle J
Addict Sci Clin Pract; 2019 Aug; 14(1):25. PubMed ID: 31366408
[TBL] [Abstract][Full Text] [Related]
24. Predictors of Medication Utilization for Opioid Use Disorder Among Medicaid-Insured HIV Patients in New York.
Choi S; Yerneni R; Healy S; Goyal M; Neighbors CJ
Am J Addict; 2020 Mar; 29(2):151-154. PubMed ID: 31951083
[TBL] [Abstract][Full Text] [Related]
25. Geographic Disparities in Availability of Opioid Use Disorder Treatment for Medicaid Enrollees.
Abraham AJ; Andrews CM; Yingling ME; Shannon J
Health Serv Res; 2018 Feb; 53(1):389-404. PubMed ID: 28345210
[TBL] [Abstract][Full Text] [Related]
26. Association of Medicaid expansion and 1115 waivers for substance use disorders with hospital provision of opioid use disorder services: a cross sectional study.
Chang JE; Cronin CE; Lindenfeld Z; Pagán JA; Franz B
BMC Health Serv Res; 2023 Jan; 23(1):87. PubMed ID: 36703146
[TBL] [Abstract][Full Text] [Related]
27. County-level access to opioid use disorder medications in medicare Part D (2010-2015).
Abraham AJ; Adams GB; Bradford AC; Bradford WD
Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272
[TBL] [Abstract][Full Text] [Related]
28. County social isolation and opioid use disorder among older adults: A longitudinal analysis of Medicare data, 2013-2018.
Yang TC; Shoff C; Kim S; Shaw BA
Soc Sci Med; 2022 May; 301():114971. PubMed ID: 35430465
[TBL] [Abstract][Full Text] [Related]
29. Examining Geographic Variation of Opioid Use Disorder Encounters in the USA.
Liu Y; Sahil S; Farr SL; Hagle HN
Adv Ther; 2022 Dec; 39(12):5391-5400. PubMed ID: 36152267
[TBL] [Abstract][Full Text] [Related]
30. Discharge locations after hospitalizations involving opioid use disorder among medicare beneficiaries.
Moyo P; Eliot M; Shah A; Goodyear K; Jutkowitz E; Thomas K; Zullo AR
Addict Sci Clin Pract; 2022 Oct; 17(1):57. PubMed ID: 36209151
[TBL] [Abstract][Full Text] [Related]
31. Impact of reported NSAID "allergies" on opioid use disorder in back pain.
Li L; Chang Y; Song S; Losina E; Costenbader KH; Laidlaw TM
J Allergy Clin Immunol; 2021 Apr; 147(4):1413-1419. PubMed ID: 32916184
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
33. Opioid analgesic and benzodiazepine prescribing among Medicaid-enrollees with opioid use disorders: The influence of provider communities.
Stein BD; Mendelsohn J; Gordon AJ; Dick AW; Burns RM; Sorbero M; Shih RA; Liccardo Pacula R
J Addict Dis; 2017; 36(1):14-22. PubMed ID: 27449904
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Samples H; Williams AR; Olfson M; Crystal S
J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
[TBL] [Abstract][Full Text] [Related]
35. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
36. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
Johnson K; Hills H; Ma J; Brown CH; McGovern M
Am J Drug Alcohol Abuse; 2021 Mar; 47(2):220-228. PubMed ID: 33054435
[No Abstract] [Full Text] [Related]
37. The interaction of neonatal abstinence syndrome and opioid use disorder treatment availability for women insured by medicaid.
Reising VA; Horne A; Bennett AC
Public Health Nurs; 2021 Jan; 38(1):98-105. PubMed ID: 33025600
[TBL] [Abstract][Full Text] [Related]
38. Association of Medicaid Expansion With Opioid Overdose Mortality in the United States.
Kravitz-Wirtz N; Davis CS; Ponicki WR; Rivera-Aguirre A; Marshall BDL; Martins SS; Cerdá M
JAMA Netw Open; 2020 Jan; 3(1):e1919066. PubMed ID: 31922561
[TBL] [Abstract][Full Text] [Related]
39. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
40. A state-wide education program on opioid use disorder: influential community members' knowledge, beliefs, and opportunities for coalition development.
Hohmann L; Phillippe H; Marlowe K; Jeminiwa R; Hohmann N; Westrick S; Fowler A; Fox B
BMC Public Health; 2022 May; 22(1):886. PubMed ID: 35508988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
